DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Dry and Wet Age-Related Macular Degeneration – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of AMD comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of AMD for each country, as…
Dry and Wet Age-Related Macular Degeneration – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key AMD patient populations covering 171 countries and more than 99% of…
Dry and Wet Age-Related Macular Degeneration | Treatment Algorithms: Claims Data Analysis | Wet Age-Related Macular Edema | US | 2022
MARKET OUTLOOK Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States, and more than half of advanced AMD patients have the wet (exudative,…
Dry and Wet Age-Related Macular Degeneration | Disease Landscape & Forecast | G7 | 2021
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors—Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis,…
Dry and Wet Age-Related Macular Degeneration | Treatment Algorithms: Claims Data Analysis | Wet Age-Related Macular Edema | US | 2021
MARKET OUTLOOK Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States, and more than half of advanced AMD patients have the wet (exudative,…
Dry and Wet Age-Related Macular Degeneration | Special Topics | Beovu: Nine Months Postlaunch for Wet AMD | US | 2020
Novartis’s Beovu (brolucizumab-dbll) was the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United…
Dry and Wet Age-Related Macular Degeneration | Special Topics | Beovu: Three Months Postlaunch for Wet AMD | US | 2020
Novartis’s Beovu (brolucizumab-dbll) is the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United…
Special Focus on Retinal Therapies: Payer Management of the Medical Benefit | Access & Reimbursement | US | 2019
As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to impose…
